Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients

Exclusion criteria

• ✕. Before the start of the study, total bilirubin ≤10 times the upper limit of normal, serum creatinine ≤1.5 times the normal value; fibrinogen can be corrected to ≥0.6g/L after infusion.
• ✕. Serum HIV antigen or antibody negative.
• ✕. HCV antibody negative, or HCV antibody positive, but HCV RNA negative.
• ✕. HBV surface antigen and HBV core antibody are both negative. If any of the above is positive, peripheral blood hepatitis B virus DNA titer detection is required, and the number of copies less than 1×103 copies/ml can be included in the group.
• ✕. LVEF ≥ 50% by cardiac echocardiography.
• ✕. Women of childbearing age must be confirmed by a pregnancy test that they are not pregnant, and are willing to take effective contraceptive measures during the test period and within ≥ 12 months after the last dose. Women during pregnancy and lactation cannot participate. Contraceptive measures should be taken during the test period and within ≥3 months after the last dose.
• ✕. Informed consent obtained.
• ✕. According to the New York Heart Association (NYHA) score, patients with heart disease of grade II or above (including grade II);